CHRS
Price
$1.02
Change
+$0.01 (+0.99%)
Updated
Apr 25, 04:59 PM (EDT)
Capitalization
117.06M
13 days until earnings call
IBO
Price
$0.43
Change
-$0.00 (-0.00%)
Updated
Apr 25, 04:59 PM (EDT)
Capitalization
5.14M
Ad is loading...

CHRS vs IBO

Header iconCHRS vs IBO Comparison
Open Charts CHRS vs IBOBanner chart's image
Coherus BioSciences
Price$1.02
Change+$0.01 (+0.99%)
Volume$14.98K
Capitalization117.06M
Impact BioMedical
Price$0.43
Change-$0.00 (-0.00%)
Volume$5.1K
Capitalization5.14M
CHRS vs IBO Comparison Chart
Loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IBO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHRS vs. IBO commentary
Apr 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a Hold and IBO is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 26, 2025
Stock price -- (CHRS: $1.01 vs. IBO: $0.43)
Brand notoriety: CHRS and IBO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 109% vs. IBO: 4%
Market capitalization -- CHRS: $117.06M vs. IBO: $5.14M
CHRS [@Biotechnology] is valued at $117.06M. IBO’s [@Biotechnology] market capitalization is $5.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.16B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 0 FA rating(s) are green whileIBO’s FA Score has 0 green FA rating(s).

  • CHRS’s FA Score: 0 green, 5 red.
  • IBO’s FA Score: 0 green, 5 red.
According to our system of comparison, CHRS is a better buy in the long-term than IBO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 5 TA indicator(s) are bullish while IBO’s TA Score has 2 bullish TA indicator(s).

  • CHRS’s TA Score: 5 bullish, 4 bearish.
  • IBO’s TA Score: 2 bullish, 8 bearish.
According to our system of comparison, CHRS is a better buy in the short-term than IBO.

Price Growth

CHRS (@Biotechnology) experienced а -9.82% price change this week, while IBO (@Biotechnology) price change was +5.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.20%. For the same industry, the average monthly price growth was -4.19%, and the average quarterly price growth was -12.04%.

Reported Earning Dates

CHRS is expected to report earnings on Jul 31, 2025.

IBO is expected to report earnings on Mar 28, 2025.

Industries' Descriptions

@Biotechnology (+7.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CHRS($117M) has a higher market cap than IBO($5.14M). IBO has higher P/E ratio than CHRS: IBO (8.10) vs CHRS (4.04). CHRS YTD gains are higher at: -26.812 vs. IBO (-70.690). CHRS has higher annual earnings (EBITDA): 37.3M vs. IBO (3.14M). CHRS has more cash in the bank: 97.7M vs. IBO (2.67M). IBO has less debt than CHRS: IBO (8.01M) vs CHRS (270M). CHRS has higher revenues than IBO: CHRS (304M) vs IBO (0).
CHRSIBOCHRS / IBO
Capitalization117M5.14M2,278%
EBITDA37.3M3.14M1,187%
Gain YTD-26.812-70.69038%
P/E Ratio4.048.1050%
Revenue304M0-
Total Cash97.7M2.67M3,662%
Total Debt270M8.01M3,372%
FUNDAMENTALS RATINGS
CHRS vs IBO: Fundamental Ratings
CHRS
IBO
OUTLOOK RATING
1..100
1992
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
45
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10086
PRICE GROWTH RATING
1..100
4698
P/E GROWTH RATING
1..100
4998
SEASONALITY SCORE
1..100
n/a30

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IBO's Valuation (45) in the null industry is somewhat better than the same rating for CHRS (90) in the Biotechnology industry. This means that IBO’s stock grew somewhat faster than CHRS’s over the last 12 months.

IBO's Profit vs Risk Rating (100) in the null industry is in the same range as CHRS (100) in the Biotechnology industry. This means that IBO’s stock grew similarly to CHRS’s over the last 12 months.

IBO's SMR Rating (86) in the null industry is in the same range as CHRS (100) in the Biotechnology industry. This means that IBO’s stock grew similarly to CHRS’s over the last 12 months.

CHRS's Price Growth Rating (46) in the Biotechnology industry is somewhat better than the same rating for IBO (98) in the null industry. This means that CHRS’s stock grew somewhat faster than IBO’s over the last 12 months.

CHRS's P/E Growth Rating (49) in the Biotechnology industry is somewhat better than the same rating for IBO (98) in the null industry. This means that CHRS’s stock grew somewhat faster than IBO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CHRSIBO
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bullish Trend 2 days ago
69%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 22 days ago
86%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IBO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TWSIX109.09N/A
N/A
American Century Select I
EKBYX11.96N/A
N/A
Allspring Diversified Cap Bldr Inst
GHAYX38.52N/A
N/A
VanEck Global Resources Fund Y
TNVIX15.22N/A
N/A
1290 GAMCO Small/Mid Cap Value I
DURCX12.95N/A
N/A
DWS ESG International Core Eq C

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with ADCT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then ADCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
-9.01%
ADCT - CHRS
39%
Loosely correlated
+5.43%
ARRY - CHRS
39%
Loosely correlated
+5.31%
AXON - CHRS
38%
Loosely correlated
+2.39%
XENE - CHRS
35%
Loosely correlated
+1.62%
AMRN - CHRS
35%
Loosely correlated
+7.92%
More

IBO and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBO has been loosely correlated with BMRN. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if IBO jumps, then BMRN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBO
1D Price
Change %
IBO100%
-0.19%
BMRN - IBO
45%
Loosely correlated
+1.29%
ITOS - IBO
41%
Loosely correlated
+4.34%
LPCN - IBO
27%
Poorly correlated
+2.58%
ADAG - IBO
25%
Poorly correlated
-6.08%
CHRS - IBO
24%
Poorly correlated
-9.01%
More